SEC 8-K and 6-K filings classified by Claude with reasoning, plus Form 4 insider transactions. Ingested from EDGAR’s filing stream in near-real time, reconciled overnight.
Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
Thomas E. Waldron was appointed as a director of Kontoor Brands, effective immediately, increasing the Board from six to seven directors. Waldron brings deep expertise from his prior role as EVP and Chief Operating Officer of Kontoor.
View raw filing on EDGAR →Robert Sharp was elected to serve as a director of the Company effective July 23, 2026, in connection with the closing of the debt exchange transaction, pursuant to the Preferred Shareholders' designation rights under the Certificate of Designation for Series A Cumulative Convertible Preferred Stock.
View raw filing on EDGAR →The 6-K discloses the appointment of Mr. Chan Ka Ki as Chief Financial Officer of Bluemount Holdings Ltd., effective July 24, 2026, to fill the vacancy created by Ms. Lui Tung Mui's resignation. While both a departure and an appointment occur, the principal disclosed action is the appointment of a named executive to a C-suite officer role, which is material to investors assessing the company's financial leadership and governance. The biographical information and confirmation of no related-party conflicts support this as a formal executive appointment disclosure.
View raw filing on EDGAR →The filing discloses both the resignation of Eugene N. Padgett as Chief Accounting Officer and the appointment of Janice Zwinggi to assume that role in addition to her CFO position. While both events occur, the principal disclosed action centers on the appointment of Zwinggi to the Chief Accounting Officer role, making exec_appointment the most salient classification. The appointment of a named executive to a principal accounting officer position is material to investors assessing the registrant's financial reporting oversight.
View raw filing on EDGAR →The filing discloses the appointment of Kevin J. Hagen as Principal Accounting Officer and Vice President and Global Controller on July 23, 2026. While the section also mentions Patrick J. Dawson's departure from the same role, the principal disclosed action centers on the appointment of a new Principal Accounting Officer—a key financial reporting position. The appointment of a new Principal Accounting Officer is material to investors as it affects the registrant's financial reporting oversight and governance structure.
View raw filing on EDGAR →Albemarle Corporation appointed Eduardo De Salles Bartolomeo as an independent director, effective July 21, 2026. Bartolomeo brings 30+ years of experience in mining and logistics, including service as CEO of Vale S.A. from 2019 to 2024, and will receive an annual retainer of $120,000 and a restricted stock grant of $170,000.
View raw filing on EDGAR →The filing discloses the appointment of Michael T. Keegan to Pioneer Bancorp's Board of Directors on July 21, 2026. The principal action is a person taking a role—specifically, a board directorship at a publicly traded financial institution. Mr. Keegan brings four decades of banking executive experience, including 31 years at M&T Bank as Senior Executive Vice President and Head of Community Banking, and will serve on the Audit and Compensation Committees. This is a material governance event affecting the composition and expertise of the board.
View raw filing on EDGAR →The 6-K discloses four new appointments to Santander UK's Executive Committee: Tom Ranger as CFO (effective 1 October 2026), Steve Affleck as Chief Accounting Officer (immediate effect), Michael Christodoulides as Chief Compliance Officer (effective 1 November 2026), and Iñaki Perkins as Head of Cards & Payments. These are material executive appointments at a major financial institution, with the CFO role being particularly significant. The filing also notes Angel Santodomingo's departure as CFO effective 31 October 2026, but the principal disclosed action is the appointment of his successor and three other senior executives.
View raw filing on EDGAR →Victor Dzau, M.D., was appointed to the Board of Directors of United Therapeutics on July 22, 2026, increasing the Board size to 13 members. As part of his appointment, Dr. Dzau received initial equity compensation consisting of 380 RSUs and 1,190 stock options, plus pro-rata awards.
View raw filing on EDGAR →The Item 7.01 disclosure announces two executive leadership changes: the promotion of Sandy Pilon to Chief Customer Experience & Values Officer and the appointment of Ryan G. Hassanein as Chief Legal & Compliance Officer. While both events are disclosed, the appointment of Hassanein as a new Chief Legal & Compliance Officer joining the Executive Leadership Team from outside the company represents the more significant material event. Executive appointments to C-suite roles are material to investors assessing management quality and governance.
View raw filing on EDGAR →Seven directors (Aaron Elliott, Ann Costello, Peter Kolchinsky, Carole Nuechterlein, Deepika Pakianathan, Randal Scott, and Douglas VanOort) and four executive officers (Aaron Elliott as CEO, Linh H. Le as CFO, Riley Ennis as Chief Product Officer, and Cheng-Ho Jimmy Lin as Chief Scientific Officer) were appointed to the New Freenome Board and management team immediately following the merger effective time.
View raw filing on EDGAR →Michael J. Maddox was appointed as a Board Member and Director of CVB Financial Corp. effective July 22, 2026, with concurrent appointment to the Bank's board and multiple board committees. While the disclosure also includes compensatory arrangements (annual director fee of $77,000 and pro-rated restricted stock grant), the principal disclosed action is the appointment of a named executive to a director role. The appointment of an experienced banking executive with 20+ years of experience and prior CEO roles is material to investors assessing board composition and governance.
View raw filing on EDGAR →Jorge J. García was appointed President and Chief Executive Officer effective September 1, 2026, succeeding retiring CEO Javier D. Ferrer. Concurrently, Lidio V. Soriano was appointed Executive Vice President and Chief Financial Officer, and Luis F. Sousa was appointed Executive Vice President and Chief Risk Officer.
View raw filing on EDGAR →Jeffrey Rowe was appointed as Executive Vice President and Chief Operating Officer of ADM, effective August 17, 2026, in a newly created role overseeing commercial businesses, global manufacturing, and R&D. Rowe brings 30+ years of industry experience, including prior service as CEO of Syngenta Group, and will report directly to the CEO.
View raw filing on EDGAR →ImageneBio appointed Yanina Grant-Huerta as Chief Financial Officer, principal financial officer, and principal accounting officer effective July 20, 2026, with a base salary of $450,000, 40% bonus eligibility, RSU and option grants, and severance benefits.
View raw filing on EDGAR →The filing discloses both a director resignation (Adam Malinowski) and an appointment (Gregory Williams to the Board effective July 23, 2026). While both events occur, the principal disclosed action centers on the appointment of Williams to fill the vacancy, with detailed background on his qualifications, experience, and compensation terms. The appointment of a new director to the board is material to investors' assessment of governance and board composition.
View raw filing on EDGAR →Nicolas Calcoen, a senior Amundi executive (Deputy CEO, Head of Strategy, Finance and Control), was appointed as a Class III director of Victory Capital Holdings effective July 23, 2026, replacing Dominique Carrel-Billiard who resigned the same date due to his departure from Amundi. The appointment was recommended by the Nominating Committee and is presented as a strategic addition to the Board.
View raw filing on EDGAR →The disclosure centers on the Board-approved appointment of William Clement as Chief Commercial Officer effective August 1, 2026, a senior executive role reporting to the CEO with responsibility for commercial strategy and the independent agent network. While the filing also mentions transitions for Jim Applegate and Matthew Dannegger, Clement's appointment is the primary announced action and the most material event—a new C-suite officer joining the Executive Leadership Team at a major transportation company. The appointment would affect investor assessment of leadership and strategic direction.
View raw filing on EDGAR →The filing discloses the appointment of Eric Seidel as a director of FreeCast, Inc., effective immediately on July 17, 2026. The Board unanimously approved both the increase in board size from three to four directors and Seidel's appointment to the Board and as the second member of the Audit Committee. This is a clear executive appointment event, material to investors as it affects board composition and governance structure, particularly given the company's Nasdaq listing compliance requirements.
View raw filing on EDGAR →The filing discloses the appointment of four officers to Fermi Inc. effective July 22, 2026: George Wentz as General Counsel, Anna Bofa as Chief Commercial Officer, Jacobo Ortiz as Chief Operating Officer, and Rob Masson as Chief Financial Officer. While the filing also includes compensatory arrangements (base salaries, bonuses, equity awards), the principal disclosed action centers on these individuals taking on executive roles. The appointments of a CFO and COO are material to a reasonable investor's assessment of the company's leadership and governance.
View raw filing on EDGAR →Shaun McMeans was appointed as a Class III director of VASO Corporation effective July 23, 2026. The disclosure emphasizes his substantial public company finance and accounting experience, including prior service as CFO of HTG Molecular Diagnostics (2012–2023), and his appointment to the audit committee as a financial expert. Director appointments are material governance events affecting the composition and expertise of the board.
View raw filing on EDGAR →The filing discloses the appointment of Melissa Anastasiou as Chief Legal Officer of Sharon AI Holdings Inc., effective July 23, 2026. The press release (Exhibit 99.1) emphasizes her extensive background (20+ years in legal, finance, and governance; 16+ years at Spark New Zealand as Executive Group General Counsel) and her role in strengthening the executive leadership team. This is a material executive appointment to a named officer position.
View raw filing on EDGAR →The filing discloses two distinct executive events under Item 5.02: (1) appointment of David Allen to the Board of Directors and as Chair of the Audit Committee, and (2) approval of an employment agreement with Mark Heinen (CFO) including base salary, bonus structure, and severance terms. While both events are material, the appointment of a new independent director to the board and audit committee chair position is the primary disclosed action, making exec_appointment the most salient classification. The compensation arrangement with Heinen is secondary and supportive of the leadership continuity narrative.
View raw filing on EDGAR →The filing discloses both a director resignation (Michael Kosloske) and the appointment of a new director (Zebulon Z. Hadley, IV) to fill the vacancy. While both events are present, the principal action emphasized in the disclosure is the appointment of Hadley, including detailed biographical information, his appointment as Chair of the Compensation Committee, and confirmation of standard director compensation arrangements. The appointment of a new board member with significant business credentials and committee leadership is the salient event for investors.
View raw filing on EDGAR →The filing discloses the appointment of Andre Mintz as a new director to CS Disco's board, effective immediately on July 22, 2026, increasing board size from eight to nine members. The disclosure includes his background, independence determination, and compensation arrangements (initial $300,000 RSU grant plus $35,000 annual cash retainer). This is a material governance event affecting board composition and investor assessment of the company's leadership.
View raw filing on EDGAR →The Board appointed Michael Kappitt as a director effective July 24, 2026, expanding the Board from seven to eight members. This is a clear executive appointment event. While the disclosure also mentions standard director compensation, the principal action disclosed is the appointment of a new director with relevant restaurant industry experience (Chief Operating and Insights Officer at Subway, former President of Carrabba's Italian Grill). Board composition changes are material to investors assessing governance and leadership.
View raw filing on EDGAR →The filing announces four new appointments to Santander UK's Executive Committee: Tom Ranger as CFO (effective 1 October 2026), Steve Affleck as Chief Accounting Officer (immediate effect), Michael Christodoulides as Chief Compliance Officer (effective 1 November 2026), and Iñaki Perkins as Head of Cards & Payments. While Angel Santodomingo's departure as CFO is also disclosed, the principal disclosed action is the appointment of these four executives to senior leadership roles. These are material C-suite appointments affecting the registrant's governance and strategic direction during the TSB integration.
View raw filing on EDGAR →The filing discloses the election of two new directors, Katherine Fogertey and Scott Mezvinsky, to Valvoline's Board effective July 22, 2026. Both are appointed to specific Board committees (Audit and Governance & Nominating, respectively). This is a clear executive appointment event. While the disclosure also includes compensatory arrangements (pro-rated RSU awards of $70,644 each), the principal action is the appointment itself, making exec_appointment the most salient classification. The appointment of experienced executives from major public companies (Shake Shack CFO and KFC CEO) to the board is material to investors assessing governance and strategic direction.
View raw filing on EDGAR →The press release announces the appointment of Christoph Erkel, Ph.D., as Chief Scientific Officer (CSO) of VERAXA Biotech AG, effective immediately. This is a named executive officer appointment to a C-suite role responsible for directing development of the company's proprietary BiTAC® platform technologies. The disclosure also notes the departure of the prior CSO, Rick Austin, Ph.D., but the principal disclosed action is Erkel's appointment to the CSO position.
View raw filing on EDGAR →Three independent directors—Zhiqiang Du, Zhuo Liang, and Qian Xu—were appointed to the board effective July 21, 2026, in connection with the Company's Nasdaq listing, with assignments to audit and compensation committees.
View raw filing on EDGAR →Joe DePinto was elected to Target's Board of Directors effective August 1, 2026, and appointed to the Audit & Risk Committee and Infrastructure & Finance Committee. This is a clear executive appointment of a director with significant retail and operational expertise (former 7-Eleven CEO). Board appointments of experienced executives are material to investors as they affect governance and strategic direction.
View raw filing on EDGAR →Edric C. Funk was elected President and Chief Executive Officer effective November 1, 2026, and immediately appointed to the Board of Directors. Richard M. Olson, the outgoing CEO, transitions to Executive Chairman. The filing also addresses compensation adjustments for both executives as part of this planned succession.
View raw filing on EDGAR →The filing discloses the appointment of Brent Stuart as Chief Executive Officer effective January 1, 2027, and his election to the Board effective July 22, 2026. While Rick Wessel's transition to Executive Chairman represents a departure from the CEO role, the principal disclosed action centers on Stuart's appointment to the CEO position and Board membership. This is a material executive succession event affecting the registrant's leadership structure.
View raw filing on EDGAR →The 6-K discloses the Board of Directors' appointment of Manuel García Diez as Chief Financial Officer (CFO) of Telecom Argentina, effective August 3, 2026. This is a clear executive appointment of a named officer to a material C-suite position. CFO appointments are material to investors as they affect financial oversight and governance.
View raw filing on EDGAR →Don W. Cummings was appointed Chief Executive Officer, President, and director effective October 1, 2026, with a compensation package of $1,050,000 base salary and $7,850,000 in long-term incentives. Brian M. Walta was simultaneously appointed Executive Vice President and Chief Financial Officer effective the same date with $600,000 base salary and $1,900,000 in long-term incentives. These appointments represent a material succession event affecting the company's top leadership.
View raw filing on EDGAR →Jennifer M. Grigsby was elected to the Board of Directors on July 21, 2026, filling the vacancy created by Stephen Lee's resignation. Grigsby, a veteran public company director and energy finance executive with over 30 years of leadership experience, was appointed to serve as Chair of the Compensation Committee and member of the Nominating & Governance and Audit Committees.
View raw filing on EDGAR →David C. Dennsteadt was named President and Chief Operating Officer effective July 17, 2026, with expanded responsibilities overseeing operating groups and leadership of strategy and corporate development.
View raw filing on EDGAR →Jeffrey Hanson appointed as permanent CEO (effective July 21, 2026) after serving as Interim CEO since February 2026; Gabe Willhite promoted to President and COO; and Scott Estes appointed Lead Independent Director. Danny Prosky retired from his CEO role as part of this leadership succession.
View raw filing on EDGAR →Four directors—Jeff Clarke, Raymond Bingham, David Golden, and Renée E. LaBran—were appointed to the Board of B&R Technology Merger Corp. effective July 20, 2026, in connection with the Company's IPO, with assignments to various board committees. This is a material governance event for the newly public SPAC.
View raw filing on EDGAR →Joseph Risico was appointed as a director to fill an existing Class I vacancy, and Ryan Daiss was appointed as President with detailed employment terms including base salary, performance bonuses, equity awards, and severance provisions.
View raw filing on EDGAR →The 6-K discloses the appointment of Yu Guo as an independent director and chair of the audit committee on July 20, 2026, following the resignation of Jiahe Liao. While both a departure and appointment occur, the principal disclosed action is the appointment of a new director to fill the vacancy, making exec_appointment the primary classification. The appointment is material because it involves a change in board composition and audit committee leadership at a Nasdaq-listed company.
View raw filing on EDGAR →The filing discloses both the resignation of CFO Polly Schneck and the appointment of John Boone as her successor, effective July 22, 2026. While both events occur, the disclosure centers substantively on Boone's appointment—his background, experience, and qualifications receive detailed treatment, whereas Schneck's departure is noted briefly as non-contentious. The appointment of a new CFO is material to investors assessing the company's financial leadership and operational continuity, particularly for a SPAC (NewHold Investment Corp IV) navigating post-IPO operations.
View raw filing on EDGAR →Susan Hunt was appointed as Chief Revenue Officer, effective July 17, 2026, to lead the Company's global revenue strategy and sales organization. Dr. Pouya Dianat transitioned from CRO to the newly created Chief Product Officer role.
View raw filing on EDGAR →Matthew Kreps was appointed to the Board of Directors of ASTROTECH Corp on July 16, 2026, increasing the board size from six to seven directors. Kreps brings extensive background in capital markets and investor relations, and received a restricted stock grant of 2,150 shares as part of his appointment.
View raw filing on EDGAR →AXT appointed Jia-Bin Duh as a Class III independent director effective July 16, 2026, expanding the Board from five to six members. Duh brings 30+ years of senior executive leadership at major technology companies (Hewlett-Packard, Microsoft, Cisco) and deep expertise in Greater China markets to support the company's subsidiary Tongmei and long-term growth strategy.
View raw filing on EDGAR →The filing discloses the appointment of Anuj Goel as Chief Financial Officer of SharonAI Holdings Inc., effective August 24, 2026. While the press release also mentions the departure of incumbent CFO Tim Broadfoot, the principal disclosed action centers on the appointment of a named executive to a C-suite officer role. The appointment is material as it affects the company's executive leadership during a growth phase.
View raw filing on EDGAR →The filing discloses the appointment of Alexander Asgary as Chief Strategy Officer effective July 16, 2026, along with a concurrent consulting agreement providing $250,000 annual compensation plus $250,000 in warrant awards. While the filing also mentions Chris Chumas's transition to EVP of a subsidiary, the principal disclosed action centers on Asgary's appointment to a C-suite role with material compensation terms, making this an executive appointment event.
View raw filing on EDGAR →The filing discloses the appointment of Mort Aaronson as a member of the Board of Directors on July 1, 2026, to fill a vacancy. The principal disclosed action is a person taking a role (board director), supported by detailed biographical information and the execution of a Director Agreement and Indemnification Agreement with specified compensation ($75,000 annually in shares). This is a clear executive appointment event.
View raw filing on EDGAR →The Board appointed Dr. Alexander Vollert as a director effective August 1, 2026. This is a clear executive appointment to the Board of Directors. While the disclosure notes that Guidewire recognized $11.3 million and $13.4 million in revenue from AXA SA (Dr. Vollert's former employer) during the relevant periods, the principal disclosed action is the appointment of a new director with significant operational and CEO experience at a major insurance company, which is material to investors assessing board composition and governance.
View raw filing on EDGAR →The exhibit discloses the appointment of Dr. Sridevi Khambhampaty as Global Head of Biologics and Senior Management Personnel, effective July 22, 2026, with induction into the Management Council. This is a senior executive appointment that would materially affect investor assessment of the company's leadership and strategic direction in its biologics division. The secondary disclosure of the auditor appointment (Deloitte Haskins & Sells, LLP) is a routine auditor change that does not override the primary event.
View raw filing on EDGAR →